Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
The malignant potential of triple negative breast cancer (TNBC) is also dependent on a sub-population of cells with a stem-like phenotype. Among the cancer stem cell markers, CD133 and EpCAM strongly correlate with breast tumor aggressiveness, suggesting that simultaneous targeting of the two surface antigens may be beneficial in treatment of TNBC. | Up-modulation of PLC-β2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133 EpCAM phenotype A promising target for preventing progression of TNBC
